The Cross-Border Biotech Blog

MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for November 17th, 2014!   This week started off with a bang, as Allergan have announced their acceptance of a $66 billion takeover bid from Actavis Plc, closing the door on a hostile offer from activist investor William Ackman and Valeant Pharmaceuticals International Inc. The deal values Allergan […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for November 10th, 2014!   This week, Profound Medical has announced their intention to go public.  In addition, Profound intends to complete a brokered private placement for gross proceeds of up to $30 million. For more details on this story as well as many more, keep reading! Mira […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 27th, 2014!   Zymeworks, which combines proprietary molecular simulation technology with high performance computing to design and optimize protein therapeutics, had some significant announcements this week, closing a $17.3 million offering while also obtaining a $375 million licensing, collaboration and equity investment arrangement with Eli Lilly.  […]

read more


Q3Banner

    In this blog, I am going to comment on the Q3 performance of the group of 60 companies which had share prices of between $0.10 and $0.99 to start 2014. Q3 Results Decliners barely outnumbered advancers by 30 to 29 (Welichem Biotech not included in this analysis) Average and median share price changes […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 20th, 2014!   Welcome to your deal review for October 20th, 2014! After a hiatus last week due to Canadian Thanksgiving and our friends to the south celebrating Columbus Day, this week’s post covers deal activity from October 6th 2014. The past two weeks saw notable […]

read more


Q3Banner

    Quiet, no momentum, but Therapeutics – Commercial companies still moved ahead There was renewed interest in the Canadian healthcare sector in the first half of 2014. The institutional interest was focused on the Therapeutics – Commercial group where there were revenues, profitability and tax-inversion potential. In Q1, there was also broader sector momentum […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 6th, 2014!   This week saw Concordia Healthcare and Tribute Pharmaceuticals wrap up significant rights acquisition deals for amounts of $90 million and $32 million, respectively.  In addition, Premier Diagnostic Health Services, Xylitol and MedMira each closed financings. For details on these stories and the rest […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for September 29th, 2014!   The past weeks saw Valeant continue its march on Allergan, this time achieving a settlement on the outstanding Delaware litigation launched by Allergan seeking to delay the takeover.  Allergan shareholders are slated to vote on Dec. 18th on whether or not to oust […]

read more


MondayDealTitle

Welcome to your Monday Biotech Deal Review for September 15th, 2014!   The last few weeks saw a steady rise in activity, with a series of financings being announced as well as closed. The Allergan-Valeant-Pershing Square saga also continues, as Allergan has requested an expedited schedule to obtain a preliminary injunction against Valeant in hopes […]

read more